Creation of Novel Candidate Biomarker Compounds
First written in FY2017. 13 of 17 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「For biomarkers related to mental health and mild cognitive impairment, we will continue to promote research and development with academia and work toward early implementation in society. For exosomes, which are expected to be used as biomarkers and functional materials and applied to treatments such as regenerative medicine, we will continue joint research with academia and other parties and pursue the development of exosome-related technologies.」
The company has broadened its exploration to mental health, mild cognitive impairment, and exosome-related fields, explicitly targeting early implementation in society and joint research. - FY2023-Q3RestatedAnnual report
「We also promoted research and development of new businesses for healthcare-related companies, resulting in higher research and development expenses.」
The company continues research and development related to new pipelines and related businesses as new businesses for healthcare-related companies. - FY2023-Q1RestatedAnnual report
「We also promoted joint research related to exosomes and research and development of new businesses for healthcare-related companies.」
The company continues research and development related to new pipelines and related businesses through joint research related to exosomes and new businesses for healthcare-related companies. - FY2022-Q3RestatedAnnual report
「In the healthcare solutions business (formerly the biomarker business), we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
The company continues to explore and consider new pipelines and biomarker-related businesses. - FY2021RaisedAnnual report
「During the consolidated fiscal year, we pursued research and development focused on developing foundational technologies for metabolome analysis, product development toward the practical application and commercialization of PEA, and exploratory research on new biomarkers.」
The company continues to explore new biomarkers and explicitly identifies joint research on a mild cognitive impairment biomarker as a business activity. - FY2021-Q3RestatedAnnual report
「We also continued working on business development and research for new pipelines and biomarker-related businesses.」
The company continues business development and research for new pipelines and biomarker-related businesses. - FY2021-Q2RestatedAnnual report
「We also continued working on business development and research for new pipelines and biomarker-related businesses.」
The company continues to explore and consider new pipelines and biomarker-related businesses as part of its business development and research activities. - FY2021-Q1RestatedAnnual report
「We also continued working on business development and research for new pipelines and biomarker-related businesses.」
The company continues to explore and consider new pipelines and biomarker-related businesses as part of its business development and research activities. - FY2020RestatedAnnual report
「We worked on considering new pipelines and related businesses.」
The company continues to explore and consider new pipelines and related businesses. - FY2020-Q3RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
The company continues to explore and consider new pipelines and biomarker-related businesses. - FY2020-Q2RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
The company continues to explore and consider new pipelines and biomarker-related businesses as part of its business development activities. - FY2020-Q1RestatedAnnual report
「We also worked on business development for new pipelines and biomarker-related businesses and on strengthening research facilities.」
The company continues to consider new pipelines and biomarker-related businesses as part of its business development activities. - FY2019RestatedAnnual report
「Worked on considering new pipelines and biomarker-related businesses」
The company continues to explore and consider new pipelines and related businesses. - FY2019-Q3RestatedAnnual report
「We also worked on considering new pipelines and biomarker-related businesses and established a sales structure for a research-use exosome purification kit.」
The company continues to consider new pipelines and biomarker-related businesses. The specific establishment of a sales structure for the exosome purification kit was separated into a new thread. - FY2019-Q2RestatedAnnual report
「We worked on considering new pipelines and related businesses.」
The company continues to consider a scope of exploration that includes new biomarker candidates and related businesses. - FY2019-Q1RaisedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
In addition to the previous creation of new biomarker candidates, the company is broadening the scope of its exploration to include consideration of new pipelines and related businesses. - FY2017First statedAnnual report
「In addition, through strengthening our research and development framework, we will work to create new biomarker candidates.」
The company outlined an initiative to strengthen its research and development framework and create new candidates separately from the existing depression pipeline.